Inspire Investing LLC Sells 519 Shares of Exelixis, Inc. $EXEL

Inspire Investing LLC reduced its holdings in Exelixis, Inc. (NASDAQ:EXEL) by 1.6% in the 2nd quarter, Holdings Channel reports. The fund owned 32,073 shares of the biotechnology company’s stock after selling 519 shares during the quarter. Inspire Investing LLC’s holdings in Exelixis were worth $1,414,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of the business. Fuller & Thaler Asset Management Inc. increased its holdings in shares of Exelixis by 2.2% in the first quarter. Fuller & Thaler Asset Management Inc. now owns 7,795,074 shares of the biotechnology company’s stock worth $287,794,000 after acquiring an additional 164,134 shares in the last quarter. AQR Capital Management LLC increased its holdings in shares of Exelixis by 73.8% in the first quarter. AQR Capital Management LLC now owns 6,893,889 shares of the biotechnology company’s stock worth $250,869,000 after acquiring an additional 2,926,884 shares in the last quarter. Invesco Ltd. increased its holdings in shares of Exelixis by 40.2% in the first quarter. Invesco Ltd. now owns 5,572,189 shares of the biotechnology company’s stock worth $205,725,000 after acquiring an additional 1,596,948 shares in the last quarter. Nuveen LLC acquired a new position in shares of Exelixis during the first quarter worth about $123,310,000. Finally, Charles Schwab Investment Management Inc. boosted its position in shares of Exelixis by 2.1% during the first quarter. Charles Schwab Investment Management Inc. now owns 3,321,407 shares of the biotechnology company’s stock worth $122,626,000 after buying an additional 69,054 shares during the period. 85.27% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

EXEL has been the subject of several recent research reports. Stifel Nicolaus upped their price objective on Exelixis from $38.00 to $41.00 and gave the stock a “hold” rating in a research report on Tuesday, July 29th. Jefferies Financial Group set a $50.00 price objective on Exelixis and gave the stock a “buy” rating in a research report on Tuesday, June 24th. Barclays initiated coverage on Exelixis in a research report on Wednesday, September 17th. They set an “equal weight” rating and a $40.00 price objective for the company. Royal Bank Of Canada reduced their price objective on Exelixis from $50.00 to $45.00 and set a “sector perform” rating for the company in a research report on Tuesday, July 29th. Finally, Morgan Stanley upped their price objective on Exelixis from $46.00 to $50.00 and gave the stock an “overweight” rating in a research report on Wednesday, September 17th. Fifteen research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $44.42.

Exelixis Stock Performance

Shares of NASDAQ EXEL opened at $38.15 on Friday. Exelixis, Inc. has a 52 week low of $25.76 and a 52 week high of $49.62. The stock has a market capitalization of $10.27 billion, a PE ratio of 18.34, a price-to-earnings-growth ratio of 0.79 and a beta of 0.38. The stock has a 50 day moving average price of $38.63 and a 200 day moving average price of $39.93.

Exelixis (NASDAQ:EXEL) last released its quarterly earnings data on Monday, July 28th. The biotechnology company reported $0.75 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.63 by $0.12. Exelixis had a return on equity of 27.47% and a net margin of 27.01%.The company had revenue of $568.26 million during the quarter, compared to analysts’ expectations of $574.36 million. During the same period last year, the firm posted $0.84 earnings per share. The business’s revenue was down 10.8% on a year-over-year basis. Exelixis has set its FY 2025 guidance at EPS. As a group, research analysts forecast that Exelixis, Inc. will post 2.04 EPS for the current year.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.